Also trades as: ACST.V (TSXV) · $vol 0M
ACST NASDAQ
Acasti Pharma Inc.
1W: +5.5%
1M: -3.5%
3M: +38.4%
1Y: +56.9%
3Y: -62.6%
5Y: -96.7%
$3.37
Last traded 2024-11-22 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
$0
+0.0% ▲
Net Income
-$9M
+25.6% ▲
EPS (Diluted)
$-0.47
+40.5% ▲
EBITDA
$0
-100.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -100.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $16M | $52M | $11K | $0 | $0 |
| Gross Profit | -$16M | -$52M | -$11K | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $6M | $10M | $5M | $10M | $2M |
| SG&A Expenses | $10M | $7M | $6M | $7M | $9M |
| Operating Expenses | $15M | $18M | $11M | $17M | $11M |
| Operating Income | -$16M | -$25M | -$11M | $0 | $0 |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $224K | $68M | $911K | $0 | $0 |
| Income Before Tax | -$10M | -$52M | -$15M | -$13M | -$9M |
| Tax Expense | -$648K | -$10M | -$2M | $0 | $0 |
| Net Income | -$10M | -$42M | -$13M | -$13M | -$9M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.60 | $-5.71 | $-1.35 | $-0.79 | $-0.47 |
| EBITDA | -$20M | -$2M | -$15M | $0 | $0 |
| Shares Outstanding | 6M | 7M | 10M | 12M | 17M |